Genmab | GEN - Biaya Penjualan





Biaya Penjualan Perubahan Tanggal
Agios Pharmaceuticals USD 1.32M 560K 2026-03
Almirall EUR 191.5M 2.29M 2025-12
Amarin USD 26.05M 1.41M 2025-12
Amgen USD 1.6B 187M 2026-03
argenx SE USD 121M 28.69M 2026-03
AstraZeneca USD -204M 3.48B 2026-03
Bayer EUR 5.23B 731M 2026-03
BioMarin Pharmaceutical USD 199.48M 37.93M 2026-03
Demant DKK 2.89B 188M 2025-12
Exelixis USD 19.95M 6.53M 2026-03
Fresenius Medical Care EUR 3.43B 248M 2026-03
Genmab DKK 81M 23M 2025-12
GlaxoSmithKline GBP 1.88B 736M 2026-03
GN Store Nord DKK 1.16B 1.08B 2026-03
GRIFOLS EUR 1.08B 214.82M 2026-03
Hikma Pharmaceutical USD 959M 492.5M 2025-12
Insmed USD 49.5M 3.34M 2026-03
Lakefront Biotherapeutics EUR 4.8M 4.34M 2026-03
Lonza CHF 2.28B 189M 2025-06
Merck EUR 2.07B 219M 2026-03
Novartis USD 3.46B 83M 2026-03
Regeneron Pharmaceuticals USD 669.4M 84.8M 2026-03
Roche Holding CHF 8.48B 4.61B 2025-12
Sanofi EUR 3.67B 621M 2026-03
UCB EUR 1.07B 146M 2025-12